JP7458318B2 - 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節 - Google Patents

癌治療のためのｓｌａｍｆ６スプライスバリアントの調節 Download PDF

Info

Publication number
JP7458318B2
JP7458318B2 JP2020542989A JP2020542989A JP7458318B2 JP 7458318 B2 JP7458318 B2 JP 7458318B2 JP 2020542989 A JP2020542989 A JP 2020542989A JP 2020542989 A JP2020542989 A JP 2020542989A JP 7458318 B2 JP7458318 B2 JP 7458318B2
Authority
JP
Japan
Prior art keywords
slamf6
cells
var3
composition
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516668A5 (cg-RX-API-DMAC10.html
JP2021516668A (ja
Inventor
ロテム，ミハエル
ミシャン，アイゼンバーグ，ガリト
ハジャジ，エマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Original Assignee
Hadasit Medical Research Services and Development Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co filed Critical Hadasit Medical Research Services and Development Co
Publication of JP2021516668A publication Critical patent/JP2021516668A/ja
Publication of JP2021516668A5 publication Critical patent/JP2021516668A5/ja
Application granted granted Critical
Publication of JP7458318B2 publication Critical patent/JP7458318B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020542989A 2018-02-12 2019-02-11 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節 Active JP7458318B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629129P 2018-02-12 2018-02-12
US62/629,129 2018-02-12
PCT/IL2019/050163 WO2019155474A1 (en) 2018-02-12 2019-02-11 Modulation of slamf6 splice variants for cancer therapy

Publications (3)

Publication Number Publication Date
JP2021516668A JP2021516668A (ja) 2021-07-08
JP2021516668A5 JP2021516668A5 (cg-RX-API-DMAC10.html) 2022-02-21
JP7458318B2 true JP7458318B2 (ja) 2024-03-29

Family

ID=67548888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542989A Active JP7458318B2 (ja) 2018-02-12 2019-02-11 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節

Country Status (5)

Country Link
US (1) US11834487B2 (cg-RX-API-DMAC10.html)
EP (1) EP3752252A4 (cg-RX-API-DMAC10.html)
JP (1) JP7458318B2 (cg-RX-API-DMAC10.html)
IL (1) IL276117B2 (cg-RX-API-DMAC10.html)
WO (1) WO2019155474A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
CN117867107A (zh) * 2023-11-24 2024-04-12 南通大学附属医院 一种构建肠癌诊断和预后相关的甲基化位点的诊断模型方法及其诊断标志物slamf6

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090017014A1 (en) 2001-08-29 2009-01-15 Valdez Patricia A Compositions and methods for the treatment of immune related diseases
JP2017503810A (ja) 2014-01-09 2017-02-02 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 癌治療のための改善された細胞組成物および方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
JP4326944B2 (ja) 2001-07-19 2009-09-09 イネイト・ファーマ ナチュラルキラー細胞活性に関与する表面分子ｎｔｂ−ａ
JP2005206478A (ja) 2004-01-20 2005-08-04 Kirin Brewery Co Ltd 樹状細胞膜分子−ＩｇＦｃ融合ポリペプチドまたはそれに対する抗体を含む医薬組成物
WO2005124346A1 (en) 2004-05-17 2005-12-29 The Board Of Trustees Of The University Of Illinois 4-1bb receptors are expressed on regulatory t-cells
EP1642905B1 (en) 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
WO2007020880A1 (ja) 2005-08-17 2007-02-22 Takara Bio Inc. リンパ球の製造方法
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
TW200823237A (en) 2006-08-28 2008-06-01 Nuvelo Inc Antibodies to NTB-A
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090017014A1 (en) 2001-08-29 2009-01-15 Valdez Patricia A Compositions and methods for the treatment of immune related diseases
JP2017503810A (ja) 2014-01-09 2017-02-02 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 癌治療のための改善された細胞組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Accession No. AK303990.1, Homo sapiens cDNA FLJ52047 complete cds, highly similar to SLAM family member 6 precursor，Database GenBank [online]，2008年07月24日，[Retrieved on 2023.06.09], Retrieved from the Internet, URL:<https://www.ncbi.nlm.nih.gov/nuccore/194384267>
Cancer Immunology Research，2018年02月01日，Vol. 6, No. 2，pp. 127-138

Also Published As

Publication number Publication date
EP3752252A1 (en) 2020-12-23
EP3752252A4 (en) 2021-11-17
US20210054043A1 (en) 2021-02-25
US11834487B2 (en) 2023-12-05
IL276117B2 (en) 2026-08-01
JP2021516668A (ja) 2021-07-08
IL276117B1 (en) 2026-04-01
WO2019155474A1 (en) 2019-08-15
IL276117A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
US20230416408A1 (en) Compositions and Methods for Targeting Stromal Cells for the Treatment of Cancer
US20230078665A1 (en) Cell compositions and methods for cancer therapy
JP5848254B2 (ja) コンジュゲート分子
AU2017336094A1 (en) HLA class I-deficient NK-92 cells with decreased immunogenicity
JP2024016155A (ja) Ｎｋｇ２ｄベースの受容体を発現する免疫細胞のフラトリサイドの減少
WO2024030970A2 (en) Genetic editing of target genes to enhance natural killer cell function
JP2025102823A (ja) 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法
AU2020307688B2 (en) Combination cancer immunotherapy
US11834487B2 (en) Modulation of SLAMF6 splice variants for cancer therapy
CN117500838A (zh) Ccr4靶向嵌合抗原受体细胞疗法
TW202444909A (zh) 用於腫瘤治療之car修飾劑的生成
Sefrin Sensitization of tumor cells for T cell mediated eradication through targeted delivery of virus-derived immunogenic peptide epitopes
HK40062145B (en) Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
de Castro Antibody-based vaccines for delivery of antigen to dendritic cells in situ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240318

R150 Certificate of patent or registration of utility model

Ref document number: 7458318

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150